Profectus BioSciences Inc., a clinical-stage vaccine company that creates vaccines to prevent and treat infectious diseases and cancers, recently began its Phase 1 clinical trial to evaluate the immunogenicity and safety of the company’s Ebola virus.
The scientists will administer different dose levels of the Ebola vaccine to different subjects. The researchers have based the vaccine on the highly attenuated vesicular stomatitis virus (VSV) vector from the company.
There will be 39 test subjects involved in the placebo-controlled, dose-escalation study. The subjects will be divided into three groups to receive the intramuscular injection at progressively higher doses.
“Profectus is pleased to announce initiation of the first step in a systematic clinical evaluation of our filovirus vaccine,”
Profectus
Chief Scientific Officer John Eldridge said. “This first study is designed to quickly establish the safety and immunogenicity of our attenuated VSV-vectored Ebola vaccine. The next step, anticipated for mid-next year, will be a trial of our trivalent vaccine to protect against all species of Ebola and Marburg viruses. That will be followed by the testing of a freeze-dried formulation that will allow field use without refrigerated storage. We want Page 2 of 3 to acknowledge the continuing financial and technical support provided by MCS-JVAP and especially for providing the funding for the execution of this Phase 1 clinical trial.”
The potential vaccine has received support from Battelle, the National Institutes of Health, the Biomedical Advanced Research and Development Authority, and the DOD Countermeasures Systems – Joint Vaccine Acquisition Program.
